Author: Ravi Shankar

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer

CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate development, and alliance management.

“We are thrilled to welcome Dr. Vnuk to Wave in a newly created leadership role as we continue to advance our pipeline to the next stages of development. Monika’s breadth of experience, including leading global business development teams and strategic asset financing, will be meaningful as we continue to expand the potential of our differentiated RNA medicines platform and support the next phase of Wave’s growth,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

“Wave has built a highly versatile and differentiated RNA medicines platform with multiple therapeutic modalities translating in the clinic. I am energized to join the company at such an exciting moment, as its science and pipeline programs create broad opportunity to advance value-creating transactions with the ultimate aim of expanding Wave’s positive impact on patients. I look forward to partnering with the Wave team to help drive the company’s growth and realize the full potential of its platform and pipeline,” said Monika Vnuk, MD, Chief Business Officer of Wave Life Sciences.

Prior to joining Wave, Dr. Vnuk served as Senior Vice President, Global Head of Partnering and Business Development for Sanofi, where she led global licensing, equity investments, and alliances. Prior to Sanofi, she was Managing Director at Blackstone Life Sciences, a private life sciences investing platform, where she was focused on late-stage product financing transactions. Dr. Vnuk spent more than a decade at Pfizer in senior business development roles, including Vice President, R&D Business Development, where she led the negotiation of the successful partnership with BioNTech directed at the global co-development and distribution of COVID-19 vaccines. Before Pfizer, she worked in investment banking at Bank of America and the life sciences venture capital firm Oxford Bioscience Partners. Dr. Vnuk earned an M.D. from Boston University School of Medicine and a B.A. in Mathematics and Philosophy from Boston University.

In connection with Dr. Vnuk joining Wave, she received a stock option to purchase 375,000 shares of common stock of Wave. The equity grant was approved by Wave’s Compensation Committee and granted to Dr. Vnuk on September 21, 2026, outside of the Wave Life Sciences, Inc. Amended and Restated 2021 Equity Incentive Plan, as an inducement material to Dr. Vnuk’s commencing employment with Wave, in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option has an exercise price of $4.25 per share, the closing price on the grant date, and vests over four years with 25% vesting on September 21, 2027, and the remainder vesting in equal quarterly installments over the following three years.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Dr. Vnuk’s leadership and global experience leading business development teams and strategic asset financing, strategic partnerships, licensing, equity investments and alliances; beliefs that Dr. Vnuk’s experience will benefit the next phase of Wave’s growth; beliefs that Wave’s portfolio of RNA medicines is differentiated, best-in-class and potentially transformative; the broad potential of Wave’s RNA medicines pipeline and oligonucleotide chemistry and any benefits that may be derived from them. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.

Panel Details
Title: “Frontiers in Neuroscience”
Date: Tuesday, September 29, 2026
Time: 10:00 AM – 10:50 AM ET

This panel will not be webcast. A recording of the panel will be available following the conference. To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth or contact cervomed@argotpartners.com. 

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Contacts:

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

ROUYN-NORANDA, Québec, Sept. 22, 2026 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX-V – FPC) (“Falco” or the “Corporation”) is proud to announce a three-year partnership with the Collectif Territoire, an organization committed to the rehabilitation of lac Osisko and to mobilizing the community around this emblematic space in Rouyn-Noranda. As part of this partnership, Falco will contribute $30,000 per year for three years, for a total commitment of $90,000. The public announcement of this partnership is part of the activities surrounding “Les Noces d’eau” event.

For Falco, this commitment goes far beyond financial support. The Collectif Territoire’s approach, based on co-creation, territorial innovation, environmental restoration and citizen participation, is directly in line with the vision that Falco wishes to put forward in the development of Falco’s Horne 5 Project. The Corporation intends to build a lasting relationship with the Rouyn-Noranda community, in which citizens can contribute to discussions about the territory and participate in initiatives that benefit their community.

“The lac Osisko Project exemplifies the kind of initiative we want to support in Rouyn-Noranda: a collaborative and place-based approach that brings residents together around sustainable environmental and community projects. Our partnership with the Collectif Territoire is a concrete expression of the relationship that Falco seeks to build with the community,” said Hélène Cartier, Vice-President, Environment, Sustainable Development and Community Relations at Falco.

Update on Falco’s Horne 5 Project
This commitment comes as Falco’s Horne 5 Project continues to move forward. Preparatory work on the project has now been underway for more than ten years. The environmental assessment conducted by the Government of Québec is now at an advanced stage and is expected to be completed in the fall of 2026.

Since the publication of the BAPE report in January 2025, Falco has responded to several sets of questions from the Ministry of the Environment, the Fight against Climate Change, Wildlife and Parks (“MELCCFP”), particularly regarding the potential impacts of the project on community services, including health care, childcare and education services, housing, emergency services and the workforce. These issues have been the subject of in-depth analyses, particularly in the Socioeconomic Assessment (in French only) published last spring.

In addition, the potential impact of project-related vibrations on the safety and continuity of operations at the Rouyn-Noranda Radiation Oncology Centre (the “Centre”) has been thoroughly assessed by independent experts, who confirmed that the mining operations and mitigation measures proposed by Falco can be carried out safely and in a manner compatible with the activities of the Centre (see Falco’s press release dated June 16, 2026).

The completion of the environmental assessment should lead to a government decision regarding the issuance of the authorization decree for the Project (the “Decree”). Obtaining the Decree will mark a decisive step for Falco and will pave the way for the development phase of the Project after obtaining all the required permits and ministerial authorizations. In the months following the Decree, Falco will continue to carry out the required studies and investigations.

The updated feasibility study published on June 17, 2026 also confirms the extent of the anticipated benefits of Falco’s Horne 5 Project for Rouyn-Noranda and Abitibi-Témiscamingue. This project represents an initial planned investment of $1.75 billion, a mine life of at least 15 years, the creation of 500 permanent jobs as well as more than $4.4 billion in taxes and mining duties over the life of the mine.

For Falco, the development of a mining project of this magnitude must be accompanied by a lasting commitment to the community that hosts it. The partnership with the Collectif Territoire is therefore part of a broader vision: to make Falco’s Horne 5 Project not only an economic driver for the region, but also a tangible contributor to the vitality, environment and quality of life of the Rouyn-Noranda community.

To learn more about:

• Collectif Territoire’s lac Osisko Project (in French): https://www.lacosisko.ca/
• The Falco Horne 5 Project (in French): Home | Falco Horne 5
• Falco Resources: Home | Ressources Falco

About Falco

Falco is one of the largest holders of mineral claims in the province of Québec, with an extensive portfolio of properties in the Abitibi-Témiscamingue greenstone belt. Falco holds rights to approximately 60,000 hectares of land in the Noranda Camp and includes 13 former gold and base metal mine sites. Falco’s main asset is the Horne 5 Project located beneath the former Horne mine, which was operated by Noranda from 1927 to 1976 and produced 11.6 million ounces of gold and 2.5 billion pounds of copper. Osisko Gold Group Inc. (formerly Osisko Development Corp.) is Falco’s largest shareholder, with a 16.0% interest in the Corporation.

For further information, please contact:

Luc Lessard
President and Chief Executive Officer and Director
514-261-3336
info@falcores.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

MONTREAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with SOQUEM Inc. (“SOQUEM”), is pleased to announce the results of the 2026 exploration campaign on the Nachicapau project (Figure 1). This exploration program follows the discovery, between 2022 and 2025, of copper, gold and silver occurrences along a 4-km-long by 1.5-km-wide corridor. These new results are reported under the Strategic Alliance between Midland and SOQUEM (the “Alliance”) in the Labrador Trough in Nunavik, Quebec.

Highlights:

• Discovery of copper, gold and silver mineralization with maximum values reaching 26.8% Cu, 0.87 g/t Au, 238 g/t Ag (grab samples from boulders) associated with digenite and malachite in veins hosted in monzonite dykes.
• Two new copper, gold and silver showings on outcrops with maximum values reaching 3.03% Cu, 0.77 g/t Au, 20.0 g/t Ag (from different grab samples).
• Identification of induced polarization (“IP”) anomalies associated with Cu, Au, Ag mineral occurrences.

The 2026 sampling campaign was conducted over a period of 5 days in June, during which a total of 54 rock samples were collected. The campaign was designed to follow up on chargeability and conductivity anomalies outlined by the Orevision® induced polarization survey conducted in 2025 (figures 2 and 3).

Assay results reveal that ten (10) grab samples show grades equal to or greater than 0.10% Cu, including four (4) samples above 1.00% Cu, reaching up to 26.8% Cu. Anomalous gold values above 0.1 g/t Au are associated with these samples, while three (3) samples exhibit silver values reaching up to 238 g/t Ag. These results highlight a close relationship between Cu, Au, Ag mineralization and the presence of monzonite dykes, alkalic ultramafic units, and regional structural features. Best results obtained in grab samples are listed in Table 1.

Table 1: Best Cu, Au, Ag Assay Results from 2026 Grab Samples.

Sample Number	NAD 83 Zone 19 (m)		Type	Host Rock	Cu	Au	Ag
	UTM E	UTM N			(%)	(g/t)	(g/t)
C2130702	558492	6277160	Boulder	Monzonite dyke	26.8	0.24	238
C2130681	559665	6275540	Boulder	Monzonite dyke	14.8	0.65	112
C2130703	558467	6277165	Boulder	Monzonite dyke	7.68	0.87	57.2
C2130684	559755	6275419	Outcrop	Monzonite dyke	3.03	0.17	20.0
C2130669	559048	6276572	Outcrop	Monzonite dyke	0.59	0.77	10.3
C2130682	559665	6275540	Boulder	Monzonite dyke	0.35	0.04	2.15
C2130704	558460	6277184	Boulder	Ultramafic schist	0.28	0.07	1.53
C2130685	559643	6275552	Outcrop	Monzonite dyke	0.10	0.01	1.37
C2130668	559054	6276556	Outcrop	Monzonite dyke	0.10	0.02	1.33
C2130651	558596	6277088	Outcrop	Ultramafic schist	0.10	0.13	0.76

Digenite, Bornite and Malachite Mineralization Associated with Monzonite Dykes

The best results of the June 2026 campaign were obtained in grab samples collected in boulders, consisting of calcite-dolomite-quartz veins crosscutting a monzonite. The mineralization is characterized by the presence of centimetre-scale patches of digenite and malachite within the veins and in their selvages (Figure 4a to 4c). Hematite is a common accessory mineral and occurs as distinctive specularite crystals. The host rock is weakly deformed and systematically altered to albite, epidote and hematite.

On outcrop, these dykes crosscut, at low angles, alkalic mafic to ultramafic volcanic units of the Murdoch Formation (Figure 4d). Copper mineralization occurs in calcite-dolomite-quartz tension gashes. Sample C2130669, which graded 0.59% Cu, 0.77 g/t Au, 10.3 g/t Ag, confirms the extension of both the mineralized zone and the monzonite dyke north of the DG-12 showing discovered in 2025 (1.46% Cu, 0.14 g/t Au, 9.20 g/t Ag in a monzonite dyke).

Samples C2130681 to C2130685, collected on either side of the DG-5 showing (2.95% Cu, 0.01 g/t Au, 27.6 g/t Ag) confirm observations and interpretations made in 2025 and extend the mineralized zones associated with monzonite dykes over a distance of 150 metres. Sample C2130684, collected in a digenite-malachite vein, yielded showing-level grades of 3.03% Cu, 0.17 g/t Au and 20.0 g/t Ag.

Mineralization Associated with Mafic to Ultramafic Volcanic Units

Three (3) samples collected in ultramafic schist and intrusive units yielded anomalous Cu, Au and Ag values. Sample C2130651, which did not appear to be mineralized, yielded values of 0.10% Cu, 0.13 g/t Au, 0.76 g/t Ag, i.e. respectively 30 to 100 times higher than regional background values. This observation suggests that copper mineralization is not exclusively found in veins but may also occur disseminated within deformed and altered ultramafic units.

2025 OreVision® Induced Polarization Survey

Follow-up work on the OreVision® induced polarization survey conducted in July 2025 helped improve our understanding of the geological setting and Cu-Au-Ag mineral occurrences on the Nachicapau project. Sedimentary units (dolomite, mudstone), mafic intrusives, and ultramafic schists can be distinguished based on resistivity and chargeability contrasts. Copper mineralization is closely linked with low-resistivity (<6,000 Ohm.m) and moderate chargeability (7–14 mV/V) zones within the ultramafic schist unit and along the contact with sedimentary units (Figure 5).

Conclusions

Cu-Au-Ag mineralization on the Nachicapau project appears to be related to:

• Deformed and altered mafic to ultramafic volcanic units of the Murdoch Formation, where it occurs as disseminated digenite and malachite
• Monzonite dykes where it occurs in veins with higher-grade Cu, Au, Ag
• Intense albite-epidote-hematite alteration occurring around the veins
• Low-resistivity copper mineralization (<6,000 Ohm.m) and moderate-chargeability
  (7–14 mV/V) zones
• A deformation corridor trending N350 that affects volcanic units
• A major shear zone that marks the contact with sedimentary units

Quality Control

Rock samples from the project are analyzed at Actlabs laboratories in Ancaster, Ontario, by ICP-MS with four-acid digestion for metals and by standard fire assay on 50-gram fractions with atomic absorption finish for gold. Exploration programs are designed, and results are interpreted by Qualified Persons employing a Quality Assurance/Quality Control program consistent with industry best practices, including the use of standards and blanks for every 20 samples.

Cautionary Statements

Grab samples are selective by nature and may not be representative of mineralized zones. Mineralization observed in samples collected from boulders, outcrops and showings mentioned in this press release is not necessarily indicative of mineralization that may be found on the project mentioned in this press release.

About the Strategic Alliance with SOQUEM

The Strategic Alliance enables Midland and SOQUEM to combine their efforts and expertise to jointly explore the excellent potential for gold and strategic minerals of the vast and underexplored Labrador Trough. The area of interest defined under the Alliance is located in Nunavik. Geologically, it covers the Labrador Trough, the Rachel-Laporte Zone, and the Kuujjuaq Domain. The area of interest extends from Schefferville in the south up to approximately 100 km northwest of Kangirsuk. Executed in November 2021, the initial agreement called for investments in exploration reaching up to $4 million over a period of four (4) years, in addition to investments on the Nachicapau project.

In 2026, the parties confirmed the continuation of the Alliance with a joint annual exploration budget of $1 million (50% Midland and 50% SOQUEM) on the Malaco Mountain and Nachicapau projects.

About SOQUEM

SOQUEM is a mineral exploration company and a subsidiary of Investissement Québec. Its mission is to explore, discover, and develop Quebec’s mineral resources. SOQUEM also contributes to maintaining a strong economy in Quebec’s regions. A proud partner and ambassador for the development of Quebec’s mineral wealth, SOQUEM relies on innovation, research and strategic minerals to be well positioned for the future.

About Midland

Midland targets the mineral potential of Quebec to make the discovery of new deposits of gold and critical metals. Midland is proud to count on reputable partners such as SOQUEM Inc., Rio Tinto Exploration Canada Inc., BHP Canada Inc., Centerra Gold Inc., Barrick Gold Corporation, Agnico Eagle Mines Limited, Wallbridge Mining Company Ltd., Fresnillo plc, Electric Elements Mining Corp., Nunavik Mineral Exploration Fund and Abcourt Mines Inc. Midland prefers to work in partnership and intends to quickly conclude additional agreements in regard to newly acquired properties. Management is currently reviewing other opportunities and projects to build up the Company portfolio and generate shareholder value.

Qualified Person and Exploration Director Richard D. St-Cyr, P.Geo., reviewed and approved this press release and the Nachicapau project data as Midland’s Qualified Person (QP) within the meaning of National Instrument 43–101.

For further information, please consult Midland’s website or contact:

Gino Roger, President and Chief Executive Officer
Tel.: 450 420-5977
Fax: 450 420-5978
Email: info@midlandexploration.com
Website: https://www.midlandexploration.com/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements include statements relating to management expectations regarding the conclusion of additional agreements in regard to newly acquired properties, and other estimates and statements that describe Midland’s future plans, objectives or goals, including words to the effect that Midland or management expects a stated condition or result to occur. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, without limitation, changes in general economic conditions and conditions in the financial markets, changes in demand and prices for minerals, failure to obtain the requisite permits and approvals from government bodies and third parties, regulatory and governmental policy changes (laws and policies) and those risks set out in Midland’s public documents, including in each management discussion and analysis, filed on SEDAR+ at www.sedarplus.com. Although Midland believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by applicable law, Midland disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/cd46a469-0e89-47b9-b764-b5c3d88292ca
https://www.globenewswire.com/NewsRoom/AttachmentNg/7d66d0d4-b053-4362-ab42-1914a717bd6b
https://www.globenewswire.com/NewsRoom/AttachmentNg/f348bf20-b379-467c-adb4-4697ee130727
https://www.globenewswire.com/NewsRoom/AttachmentNg/d45930ab-89a9-4a3a-a6ee-3e76a351543a
https://www.globenewswire.com/NewsRoom/AttachmentNg/aca54b4f-ff84-4f5e-ab73-aeabc030038c

Calgary, Alberta, Sept. 22, 2026 (GLOBE NEWSWIRE) — Seegnal Inc. (TSXV:SEGN) (“Seegnal” or the “Company”), today announced that its investor relations technologies and services agreement dated March 26, 2026 (“Services Agreement”) with CapitaLynx Ltd. will conclude effective September 26, 2026.

The Services Agreement was previously disclosed in the Company’s news release dated April 1, 2026. During the engagement, the Company rebuilt its investor materials, narrative positioning and investor portal and upgraded its core investor relations assets. The Company intends to continue to use those materials, infrastructure and technologies. The Company wishes to thank CapitaLynx for its services and contributions during the engagement.

About Seegnal
Seegnal Inc. (TSXV: SEGN) is an innovative healthcare technology company dedicated to reducing medication-related harm where care begins. The Company’s SaaS-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age, and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing, and advance a more personalized standard of patient care. Seegnal’s technology is deployed across healthcare settings and is used by more than 15,000 clinicians in daily practice. For additional Company information, please visit https://investors.seegnal.com/ and follow us on LinkedIn.

Seegnal Media Contact:
Elad Bibi-Aviv
Chief Executive Officer press@seegnal.com
+972-52-533-0856
www.seegnal.com

Forward-Looking Information
This press release contains “forward-looking information” or “forward-looking statements” within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the “About Seegnal” section of this press release, are forward-looking. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as “anticipate”, “believes”, “estimates”, “expects”, “intends”, “may”, “should”, “will” or variations of such words or similar expressions. More particularly, and without limitation, this press release contains forward-looking information or forward-looking statements with respect to the conclusion of the Services Agreement and the Company’s intention to continue using materials, infrastructure and technologies developed during the engagement. Seegnal cautions that all forward-looking information and forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including expectations and assumptions concerning Seegnal and its products as well as other risks and uncertainties, including those described in Seegnal’s filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking information or forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking information or forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking information and forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking information or forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORT WORTH, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — CorVel Corporation (NASDAQ: CRVL), a national provider of risk management and healthcare solutions, today announced the availability of its Care^MC Accelerator for Guidewire ClaimCenter, enabling Managed Care services to be initiated and managed directly within the claims workflow.

Designed for Guidewire Cloud and aligned with Guidewire standards, the Care^MC Accelerator connects claims activity with Managed Care operations through secure Single Sign‑On (SSO) and structured data exchange. This integration delivers a streamlined experience where key actions and information are available at the point of decision, reducing friction and improving workflow efficiency.

Streamlined Access and Data Exchange

The Care^MC Accelerator, now available on Guidewire Marketplace, enables carriers to connect claims and Managed Care processes through:

• Direct access to CorVel Managed Care services from within ClaimCenter
• Secure SSO to support streamlined navigation across systems
• Automated transfer of claim and injury data to initiate services
• Real‑time return of Managed Care status updates, recommendations, and outcomes

By coordinating how information moves across systems, teams gain clearer insight into case activity and can take action without unnecessary disruption.

Practical Benefits for Claims and Managed Care Teams

With this integration, users can:

• Initiate and coordinate care services within their existing claims environment
• Eliminate duplicate data entry and reduce administrative steps
• Track Managed Care activity in real time
• Make faster, more informed decisions with guided visibility into care activity

Scalable Integration Built for Adoption

CorVel’s Accelerator supports flexible implementation and long‑term scalability. By leveraging Guidewire integration standards, the Care^MC Accelerator reduces technical complexity while allowing carriers to configure workflows that align with their operating models.

Key advantages include:

• Faster and more predictable implementation timelines
• Reduced demand on IT resources
• Configurable workflows and business rules
• Simplified evaluation and deployment through the Guidewire Marketplace

Supporting Modern Claims Operations

This integration enables managed care to function as a coordinated part of the claims process rather than a separate downstream activity. Teams benefit from improved continuity and greater confidence that medical aspects of a claim are being addressed alongside claims handling.

“Moving to CorVel has never been easier, not because claims environments are simple, but because our integrations are designed to align with how carriers operate,” said Ron Wojciechowski, Senior Vice President of Payer Technical Solutions at CorVel. “Our Care^MC Accelerator supports efficient adoption while helping teams stay focused on outcomes.”

Additional details are available through Guidewire Marketplace.

About CorVel
CorVel Corp. applies technology, including artificial intelligence, machine learning, and natural language processing, to enhance the management of episodes of care and related health care costs. We partner with employers, third-party administrators, insurance companies, and government agencies in managing workers’ compensation and health, auto, and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel’s customized services, delivered locally, are backed by a national team to support our partners and their customers and patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates and projections about the Company, management’s beliefs, and certain assumptions made by the Company, and events beyond the Company’s control, all of which are subject to change. Such forward-looking statements include, but are not limited to, improved productivity resulting from automation and augmentation across enterprise business systems. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company’s filings with the Securities and Exchange Commission, including but not limited to “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2025, September 30, 2025, and December 31, 2025. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

Contact: Melissa Storan
Phone: 949-851-1473
www.corvel.com

Award Strengthens Regional Supply Chain and Advances Edible Garden’s Zero-Waste Inspired® Mission and Farm-to-Formula® Platform

BELVIDERE, NJ, Sept. 22, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has been awarded fresh-cut herb business through an additional Walmart distribution center serving the Upper Midwest. The award builds upon the Company’s recently announced expansion with Walmart in the Mid-Atlantic region and extends Edible Garden’s growing retail presence into the Upper Midwest.

The additional distribution center will be serviced by Edible Garden Heartland in Grand Rapids, Michigan, further diversifying the facility’s customer base while supporting the Company’s strategy of creating a more centralized, scalable and efficient distribution network. The Company believes the award has the potential to increase fresh-cut herb volume and improve operating efficiencies as demand grows, while providing a foundation for Edible Garden to pursue additional stores, products and regional opportunities with Walmart and other major retailers.

“This award represents another important expansion of our relationship with Walmart and establishes an additional supply-chain position for Edible Garden in the Upper Midwest,” said Jim Kras, Chief Executive Officer of Edible Garden. “We believe it reflects Walmart’s confidence in our ability to consistently deliver fresh, high-quality herbs while meeting the food-safety, reliability, and service requirements of one of the world’s largest retailers. Just as importantly, the award advances our transition toward a more efficient distribution-center model. By consolidating shipments through Walmart’s distribution network, we believe we can improve route density, reduce fragmented deliveries and scale more efficiently as demand grows, while reducing unnecessary transportation, handling, and potential food waste. This approach supports our Zero-Waste Inspired® mission while building a stronger and more resilient distribution platform that can support our fresh herb business today and provide a commercial foundation for future Farm-to-Formula® products and other opportunities across our broader food and nutrition portfolio.”

Edible Garden’s distribution strategy is supported by its proprietary GreenThumb 2.0™ technology, which helps the Company synchronize growing, inventory, and retailer demand. By improving visibility across its supply chain, the Company seeks to enhance forecasting and fulfillment, preserve product freshness and reduce excess inventory and waste.

Edible Garden’s work with Walmart also reflects the Company’s broader commitment to sustainable operations. The Company is a multi-year participant in Walmart’s Project Gigaton and has been recognized as a Giga Guru for its efforts to measure, manage and reduce emissions across its operations and supply chain.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the recent implantation of the 1,000^th Tibia Nail using its latest Pediatric Nailing Platform (PNP).

The PNP Tibia System was designed to bring a world-class, pediatric-focused nailing system to surgeons, enabling the use of rigid tibial nails in pediatric patients.

OrthoPediatrics’ introduction of the 7mm cannulated rigid tibial nail, the only product of its size, enables surgeons to treat patients who have previously been untreatable with adult systems. In fact, nearly 20% of all nails implanted by OrthoPediatrics have been the smallest 7mm size available. The implant is available in 7mm-12mm diameters.

Joe Hauser, President of Trauma & Deformity, stated, “The rapid adoption of this system demonstrates that OrthoPediatrics is filling a critical void in implant offerings to our core customer. The surgeon design team and our OrthoPediatrics engineers were meticulous in developing a system purpose-built for the needs of pediatric patients, and it is proving to be a valuable tool in treating over 1,000 kids with tibia fractures.”

The system includes small instruments to access the intramedullary canal, smaller overall nails, fixation options designed to avoid the physis, and instrumentation supporting both traditional and suprapatellar approaches.

PNP Tibia is currently available in five markets, with a European launch planned for 2027.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

Investor Contact
Philip Taylor
Gilmartin Group
philip@gilmartinir.com

– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –

– Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses –

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that new data from the Phase 3 INDIGO trial evaluating obexelimab in immunoglobulin G4-related disease (IgG4-RD) will be presented at two upcoming scientific meetings: the 6^th International Symposium on IgG4-Related Disease, taking place October 8-10, in Cambridge, Massachusetts, and American College of Rheumatology (ACR) Convergence 2026, taking place November 6-11, 2026, in Orlando, Florida.

Longer-term flare protection and safety data from the INDIGO open-label extension will be presented on October 10 at the 6^th International Symposium on IgG4-Related Disease. Additional presentations across both meetings include analyses evaluating glucocorticoid-associated toxicity and vaccine responses among patients with IgG4-RD treated with obexelimab.

“Zenas is committed to advancing the scientific understanding of IgG4-RD and the potential role of obexelimab in addressing the needs of people living with this rare, chronic, immune-mediated disease,” said Lisa von Moltke, MD, Head of Research and Development and Chief Medical Officer of Zenas. “The upcoming presentations at the IgG4ward! 6^th International Symposium on IgG4-RD and ACR Convergence 2026 build on the Phase 3 INDIGO results presented earlier this year and reflect our continued focus on advancing therapies that may help people living with IgG4-RD.”

Presentation Details

Details of 6^th International Symposium on IgG4-Related Disease Presentations:

Title: Clinically Meaningful Influenza and SARS-CoV-2 Vaccine Responses Following Treatment-Free Window of Obexelimab in Patients with IgG4-RD
Presenting Author: Guy Katz, MD, MS – Massachusetts General Hospital
Session: Poster Viewing Session
Session Date & Time: Thursday, October 8; 5:00-7:00pm ET
Location: Charles Hotel-Boston

Title: Obexelimab Reduced Glucocorticoid-Associated Toxicity in Patients with IgG4-Related Disease: Results From the Phase 3 Randomized, Placebo-Controlled INDIGO Trial
Presenting Author: Matthew Baker, MD, MS – Stanford University
Session: Oral Presentation
Session Date & Time: Saturday, October 10; 9:00am ET
Location: Charles Hotel-Boston

Title: Longer-Term Efficacy and Safety of Obexelimab in IgG4-Related Disease: Results from the Phase 3 INDIGO Open-Label Extension
Presenting Author: Emma Culver, Dphil, MBChB – University of Oxford
Session: Oral Presentation
Session Date & Time: Saturday, October 10; 9:40am ET
Location: Charles Hotel-Boston

Details of ACR Convergence 2026 Presentations:

Title: Obexelimab Reduced Glucocorticoid-Associated Toxicity in Patients with IgG4-Related Disease: Results from the Phase 3 Randomized, Placebo-Controlled INDIGO Trial
Presenting Author: Matthew Baker, MD, MS – Stanford University
Session: Miscellaneous Rheumatic & Inflammatory Diseases I
Session Date & Time: Monday, November 9; 1:30pm-1:45pm ET
Abstract Number: 1882
Location: Oral presentation, W304 A-H

Title: Clinically Meaningful Influenza and SARS-CoV-2 Vaccine Responses Following Treatment-Free Window of Obexelimab in Patients with IgG4-RD
Presenting Author: Guy Katz, MD, MS – Massachusetts General Hospital
Session: Miscellaneous Rheumatic & Inflammatory Diseases; Poster Session C
Session Date & Time: November 10; 10:30am-12:30pm ET
Abstract Number: 2612
Location: Poster Hall

About Obexelimab
Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. This unique inhibitory mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively modulate the pathogenic role of the B cell lineage in chronic autoimmune disease.

Obexelimab has been evaluated in nine clinical trials in a total of 667 subjects, including INDIGO. Obexelimab was well tolerated and demonstrated clinical activity across these clinical trials.

Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026.

About IgG4-RD
IgG4-related disease (IgG4-RD) is a rare, chronic immune-mediated disease that can cause inflammation and fibrosis in multiple organs throughout the body. Because symptoms can appear suddenly or develop gradually—and may be mistaken for other conditions—many people face a 5–7-year journey to diagnosis. IgG4-RD can worsen and cause irreversible damage if it is not diagnosed and managed properly. About 20,000 people in the United States have been diagnosed with IgG4-RD, but the true number of people living with the disease may be closer to 40,000 because some individuals remain undiagnosed.

About Zenas BioPharma
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements.” In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward looking statements include, but are not limited to, the anticipated timing or likelihood of regulatory submissions and approvals, and the outcome of interactions with regulatory authorities; the therapeutic potential of the Company’s product candidates; the Company’s expectations regarding the potential commercialization, estimated market size and market opportunities of its product candidates; and the timing of reporting the topline results of obexelimab in SLE. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results, performance or achievements to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements; the Company’s ability to obtain regulatory approval to commercialize its product candidates; risks related to the manufacturing of the Company’s product candidates and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the its license obligations; significant political, trade, and regulatory developments, including changes in relations between the U.S. and China; risks related to the operations of the Company’s suppliers, many of which are located outside of the United States, including the Company’s current sole contract manufacturing organization for obexelimab drug substance and drug product, WuXi Biologics (Hong Kong) Limited, and our partner, InnoCare, both of which are located in China; the risk that the Company’s indebtedness could adversely affect the Company’s financial condition or restrict the Company’s future operations; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented from time to time by our subsequent filings with the Securities and Exchange Commission (the “SEC”), as well as other information we file with the SEC. The forward-looking statements in this press release are based upon information available to the Company as of the date of this press release and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete. Because forward-looking statements are inherently subject to risks and uncertainties, these forward-looking statements should not be relied upon as guarantees of future events. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Contacts:

Investors:
Argot Partners
Zenas@argotpartners.com

Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Ruihe Data Technology Holdings Limited (HKEX: 3680; OTCQX: RHDTY), an investment holding company, has qualified to trade on the OTCQX® Best Market. Ruihe Data Technology Holdings Limited upgraded to OTCQX from the Pink Limited™ Market.

Ruihe Data Technology Holdings Limited begins trading today on OTCQX under the symbol “RHDTY.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Ruihe Data Technology Holdings Limited is a leading enterprise in China’s data intelligence and marketing technology. It provides financial institutions, government agencies, and enterprises with solutions and consulting services in big data decision-making, artificial intelligence, digital marketing, and the domestic information technology innovation industry.

Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

“The Company regards the upgrade from the Pink Limited Market to the OTCQX Market as a significant milestone. It showcases the Company’s qualifications and raises its profile among U.S. investors. This upgrade is expected to broaden the Company’s investor base and enhance liquidity, aligning with the interests of the Company and its shareholders,” said Ruihe Data Technology Holdings Ltd. Chairman and CEO Shouguang Xue.

Trading in Asia Pacific securities on the OTC Markets reached U.S. $19.49B in the second quarter of 2026, representing a 34.1% increase over Q2 2025. OTC Markets recorded U.S. $453.34B in total dollar volume in the first half of the year. Asia Pacific markets ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Ruihe Data Technology Holdings Limited
The Company is a company incorporated in the Cayman Islands with limited liability and is an investment holding company. The Group is principally engaged in the provision of data solutions, integrated sales of hardware and software and related services, information technology maintenance and support services, commodity trading, cryptocurrency mining and investment in high-tech business

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com